NephroGenex Inc

NephroGenex — Investor Presentation (May 2016)

32 slides from NephroGenex's investor presentation, May 13, 2016

  1. Slide 1: Corporate Presentation May 2016

    Corporate Presentation May 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe

  3. Slide 3: Opportunity

    Opportunity 3  NephroGenex, Inc., a specialty pharmaceutical Company that was focused on the development of therapeutics to treat kidney disease, determined based on financial considerations to pause its two key programs: 1) its phase 3 clinical program for oral Pyridorin for the treatment of diabe

  4. Slide 4: NephroGenex Pipeline

    NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop

  5. Slide 5: Oral Pyridorin – Significant Market Potential

    Oral Pyridorin – Significant Market Potential 5 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 22 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U

  6. Slide 6: Pyridorin – Mechanism of Action

    6 Pyridorin – Mechanism of Action

  7. Slide 7: Clinical Overview: Ph2 Data in Target Ph3 Population

    7 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC) PYR-210 (52 Wk PIVOTAL Ph 2b Study) PYR-206 PYR-205/207 (26 Wk Phase 2a Studies)

  8. Slide 8: PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients

    PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients 8

  9. Slide 9: Preclinical and Clinical Safety

    9 Preclinical  No toxicity signal in multiple species: ― 13 - 100x human blood level in studies up to 12 months ― no signs of intolerance, toxicity or behavioral changes at doses of 50, 100 and 200 mg/kg in administered once daily through IV infusion for over 30 minutes for seven consecutive days 

  10. Slide 10: Overview of Phase 3 Study - PIONEER

    Objective:  Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population:  Type 2 diabetic subjects  Baseline SCr >1.3 and <3.0 mg/dL (eGFR > 20 ml/min)  Protein/creat

  11. Slide 11: Phase 3 Progress (April 30, 2016)

    11 Phase 3 Progress (April 30, 2016)  To date, 328 patients (out of 600) were enrolled during the first of two phase 3 trials required for approval (total of 1,200 patients)  The study has successfully passed three DSMB reviews (2/21/21015; 7/29/2015; 1/21/2016)  The study was halted due to finan

  12. Slide 12: PYR-311 – Proposed Statistical Analysis

    12 Review the statistical analysis plan with statistician prior to unblinding the data. Proposed data analysis to include:  Mean change from baseline in SCr at 6 months, 9 months & 12 months: ― Pyridorin vs placebo ― ITT analysis  Sensitivity analysis: ― Per-protocol analysis ― Impact of outliers

  13. Slide 13: Oral Pyridorin (for DN) Exclusivity Patents and NCE

    No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S.  Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension)  Method of manufacture patent February 2025  NCE - 5 year exclu

  14. Slide 14: Acute Kidney Injury (AKI) and IV Pyridorin

     Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality (AKI affects approximately 2.5 million U.S. hospitalized patients annually)  The major causes of hospital-acquired AKI are de

  15. Slide 15: AKI – Preclinical Ischemia-reperfusion Model

    15 PYR treatment was provided to mice in drinking water starting 72 h prior to injury and continued until sacrificed. AKI – Preclinical/Ischemia-reperfusion (I/R) Model NF = nephrectomy

  16. Slide 16: IV Pyridorin for AKI Exclusivity

    16 Methods for treating or limiting development of AKI Patent Exclusivity  Pending first U.S. non-provisional application that, if issued as a patent, would expire in October 2026 absent any patent term adjustment/extension  Pending second family of applications with currently pending U.S. and PCT

  17. Slide 17: Summary of Phase 2 Data

    Summary of Phase 2 Data

  18. Slide 18: Phase 2a Studies PYR-206 and PYR-205/207

    PYR-206 (Safety & Tolerability Efficacy not pre-specified) PYR-205/7 (Dose Escalation) Phase 2a Studies - 26 Wk in Type 1 & 2 Diabetic Subjects With Mild/Moderate Nephropathy 18

  19. Slide 19: Phase 2a Studies – Merged Dataset

    19 Phase 2a Studies – Merged Dataset: PYR-206 & PYR205/207 Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy. Am J Nephrol 2007;27:605–614 SCr change fro

  20. Slide 20: Pivotal Ph 2b Dose-Ranging Study in Type 2 Diabetic Subjects

    20 Pivotal Ph 2b Dose-Ranging Study – 52 wks in Type 2 Diabetic Subjects with Overt Nephropathy (150 mg bd and 300 mg bd) Phase 3 study population agreed with FDA in the SPA

  21. Slide 21: Importance of Stable Standard of Care in DN Trials

    21  The FDA is aware of this observed effect of possible acute changes in SCr arising from ACEi/ARB/BP medication changes that could impact the SCr baseline and SCr-based calculated treatment effects.  A pre-specified analysis was included in the Phase 2b Statistical Analysis Plan to evaluate the

  22. Slide 22: Post-hoc Analysis of Phase 2b Endpoint

    22 Post-hoc Analysis of Phase 3 Endpoint in Pivotal Ph 2b Study

  23. Slide 23: Pyridorin Safety Profile: PYR-210

    Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300 mg BID Pyridorin Safety Profile: PYR-210 23 Most Reported Adverse Events Most Reported Serious Adverse Events  No meaningful differences between groups

  24. Slide 24: Appendix

    Appendix

  25. Slide 25: Serum Creatinine and eGFR Definitions

    Definition  Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood  Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar

  26. Slide 26: PYR-206 – Phase 2a Study (50 mg BID)

    26 PYR-206 – 24 Week Phase 2a Study (50 mg BID) PYR-206 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 128  Population: Type 1 or type 2 diabetes ― Baseline SCr ≤ 2.0 mg/dL ― Urinary Protein: Creatinine Ratio (PCR) >30

  27. Slide 27: Phase 2a PYR-206 Post-hoc Analysis

    NephroGenex 6 Month Phase 2a PYR-206 Post-hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Treatment Effect P value All Patients 65, 63 1.27  0.34 1.33  0.38 0.12  0

  28. Slide 28: PYR-205/207 – Phase 2a Study (250 mg BID)

    28 PYR-205/207 – 24 Week Phase 2a Study (250 mg BID) PYR-205/207 Multi-center, randomized, double- blind, dose-escalating, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 84  Population: Type 1 or type 2 diabetes ― SCr ≤ 2.0 mg/dL (PYR- 205); ― SCr >2 mg/dL a

  29. Slide 29: Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis

    NephroGenex 6 Month Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure control Pyridorin at a 250 mg bid dose is well tolerated and slows

  30. Slide 30: PYR-210 – Study Baseline Characteristics

    30 PYR-210 – 52 Week Study - Baseline Characteristics

  31. Slide 31: Phase 2b PYR-210 Pre-Specified Analysis: SOC vs. Non-SOC

    NephroGenex 12 Month Phase 2b PYR-210 Pre-Specified Analysis: SOC at Screening vs. Non-SOC at Screening Patients analysis Type 2 Diabetic Nephropathy Patients With and Without SOC1 at screening – 300 and 150 mg bid 1 SOC: ACEI/ARB therapy and blood pressure control. Patients not on SOC at screening

  32. Slide 32: Primary and Secondary Endpoints

    Primary Endpoints:  Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: ― A serum creatinine (SCr) increase of ≥50

NephroGenex — Investor Presentation (May 2016) on 6ix